## Jiejie Li

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3552065/publications.pdf

Version: 2024-02-01

516561 434063 1,104 32 16 31 citations h-index g-index papers 32 32 32 1837 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	The Contribution of Inflammation to Stroke Recurrence Attenuates at Low LDL-C Levels. Journal of Atherosclerosis and Thrombosis, 2022, 29, 1634-1645.	0.9	3
2	Interleukin-6 as Predictor of One-Year Cognitive Function After Ischemic Stroke or TIA. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 391-399.	1.0	5
3	Predictive values of baseline matrix metalloproteinase 9 levels in peripheral blood on 3â€month outcomes of highâ€risk patients with minor stroke or transient ischemic attack. European Journal of Neurology, 2022, 29, 2976-2986.	1.7	2
4	Association of residual inflammatory risk with stroke recurrence in patients with acute ischaemic stroke or transient ischaemic attack. European Journal of Neurology, 2022, 29, 2258-2268.	1.7	3
5	LDL-C levels, lipid-lowering treatment and recurrent stroke in minor ischaemic stroke or TIA. Stroke and Vascular Neurology, 2022, 7, 276-284.	1.5	10
6	Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study. Journal of Neuroinflammation, 2022, 19, .	3.1	29
7	Association Between Highâ€Sensitivity Câ€Reactive Protein and Prognosis in Different Periods After Ischemic Stroke or Transient Ischemic Attack. Journal of the American Heart Association, 2022, 11, .	1.6	9
8	Association of elevated hs-CRP and multiple infarctions with outcomes of minor stroke or TIA: subgroup analysis of CHANCE randomised clinical trial. Stroke and Vascular Neurology, 2021, 6, 80-86.	1.5	15
9	Residual Recurrence Risk of Ischemic Cerebrovascular Events: Elements and Implications. Neuroscience Bulletin, 2021, 37, 1361-1364.	1.5	2
10	Residual Inflammatory Risk Predicts Poor Prognosis in Acute Ischemic Stroke or Transient Ischemic Attack Patients. Stroke, 2021, 52, 2827-2836.	1.0	27
11	Residual Risk and Its Risk Factors for Ischemic Stroke with Adherence to Guideline-Based Secondary Stroke Prevention. Journal of Stroke, 2021, 23, 51-60.	1.4	29
12	Lp-PLA2 and dual antiplatelet agents in intracranial arterial stenosis. Neurology, 2020, 94, e181-e189.	1.5	4
13	Effect of Stress Hyperglycemia on Neurological Deficit and Mortality in the Acute Ischemic Stroke People With and Without Diabetes. Frontiers in Neurology, 2020, $11$ , 576895.	1.1	26
14	Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 839-846.	1.1	18
15	High-sensitive C-reactive protein and dual antiplatelet in intracranial arterial stenosis. Neurology, 2018, 90, e447-e454.	1.5	17
16	Impact of Glycemic Control on Efficacy of Clopidogrel in Transient Ischemic Attack or Minor Stroke Patients With <i>CYP2C19</i> Genetic Variants. Stroke, 2017, 48, 998-1004.	1.0	14
17	High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome. Stroke, 2016, 47, 2025-2030.	1.0	70
18	Blood Biomarkers in Minor Stroke and Transient Ischemic Attack. Neuroscience Bulletin, 2016, 32, 463-468.	1.5	13

#	Article	IF	CITATIONS
19	Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke. Neurology, 2015, 84, 1330-1336.	1.5	26
20	Soluble CD40L Is a Useful Marker to Predict Future Strokes in Patients With Minor Stroke and Transient Ischemic Attack. Stroke, 2015, 46, 1990-1992.	1.0	35
21	Association of Lp-PLA <sub>2</sub> -A and early recurrence of vascular events after TIA and minor stroke. Neurology, 2015, 85, 1585-1591.	1.5	43
22	Glutamate transporter type 3 knockout leads to decreased heart rate possibly via parasympathetic mechanism. Transgenic Research, 2013, 22, 757-766.	1.3	5
23	A case of exacerbated multiphasic disseminated encephalomyelitis after interferon beta treatment. Journal of the Neurological Sciences, 2013, 325, 176-179.	0.3	9
24	Homocysteine and C-Reactive Protein Associated with Progression and Prognosis of Intracranial Branch Atheromatous Disease. PLoS ONE, 2013, 8, e73030.	1.1	24
25	Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease. Progress in Neurobiology, 2012, 97, 1-13.	2.8	235
26	Lidocaine attenuates cognitive impairment after isoflurane anesthesia in old rats. Behavioural Brain Research, 2012, 228, 319-327.	1.2	78
27	Pyrrolidine dithiocarbamate attenuates brain $\hat{A}^2$ increase and improves long-term neurological outcome in rats after transient focal brain ischemia. Neurobiology of Disease, 2012, 45, 564-572.	2.1	16
28	Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacology Biochemistry and Behavior, 2012, 101, 564-574.	1.3	223
29	Lentiviral-Mediated shRNA Silencing of PDE4D Gene Inhibits Platelet-Derived Growth Factor-Induced Proliferation and Migration of Rat Aortic Smooth Muscle Cells. Stroke Research and Treatment, 2011, 2011, 1-7.	0.5	8
30	Expression of the transcription factor regulatory factor X1 in the mouse brain. Folia Histochemica Et Cytobiologica, 2011, 49, 344-351.	0.6	11
31	Meta-analysis of association between variation in the PDE4D gene and ischemic cerebral infarction risk in Asian populations. Neurogenetics, 2010, 11, 327-333.	0.7	30
32	Meta-Analysis of Genetic Studies from Journals Published in China of Ischemic Stroke in the Han Chinese Population. Cerebrovascular Diseases, 2008, 26, 48-62.	0.8	65